X

Drug Profile

Research programme: spinal muscular atrophy therapeutics - Summit

Latest Information Update: 10 Feb 2009

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VASTox
Class Small molecules
Mechanism of Action Survival of motor neuron 1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Spinal muscular atrophy

Most Recent Events

10 Feb 2009 Discontinued - Preclinical for Spinal muscular atrophy in United Kingdom (PO)
20 Jul 2007 VASTox is now called Summit
21 Jul 2005 Preclinical trials in Spinal muscular atrophy in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com